A Phase I Dose Escalation Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2017
At a glance
- Drugs Tabelecleucel (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 03 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Sep 2018.
- 03 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 10 Jun 2017 Biomarkers information updated